ReviewMolecular bioSystems2012
The spectral networks paradigm in high throughput mass spectrometry.
Review in Molecular bioSystems, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 91 citations in OpenAlex.
- Multiple Spectrum Alignment for Molecular Networking Exploration and Discovery.Journal of the American Society for Mass Spectrometry · 2026Article
- MS-RT: A Method for Evaluating MS/MS Clustering Performance for Metabolomics Data.Journal of proteome research · 2025Article
- Extraction, Isolation, and Structural Elucidation of Acylated Triterpene Saponins from Asteraceae Family.Methods in molecular biology (Clifton, N.J.) · 2025Article
- [Advances in molecular networking technology for discovering emerging contaminants and transformation products].Se pu = Chinese journal of chromatography · 2025Review
- Network Topology Evaluation and Transitive Alignments for Molecular Networking.Journal of the American Society for Mass Spectrometry · 2024Article
- Spectroscape enables real-time query and visualization of a spectral archive in proteomics.Nature communications · 2023Article
- Lipidomic chemotaxonomy aligned with phylogeny of Halobacteria.Frontiers in microbiology · 2023Article
- The Cooked Meat Carcinogen 2-Amino-1-methyl-6-phenylimidazo[4,5-Chemical research in toxicology · 2022Review
- Cytotoxic Indolocarbazoles From a Marine-DerivedFrontiers in microbiology · 2022Article
- A conversation between hyphenated spectroscopic techniques and phytometabolites from medicinal plants.Analytical science advances · 2021Review
- In Vitro Metabolism Study of Seongsanamide A in Human Liver Microsomes Using Non-Targeted Metabolomics and Feature-Based Molecular Networking.Pharmaceutics · 2021Article
- Comprehensive Analysis of DNA Adducts Using Data-Independent wSIM/MSAnalytical chemistry · 2021Article
- Leveraging orthogonal mass spectrometry based strategies for comprehensive sequencing and characterization of ribosomal antimicrobial peptide natural products.Natural product reports · 2021Review
- Methods for Proteogenomics Data Analysis, Challenges, and Scalability Bottlenecks: A Survey.IEEE access : practical innovations, open solutions · 2021Article
- Screening Immunoactive Compounds ofFrontiers in pharmacology · 2020Article
- Alphabet Projection of Spectra.Journal of proteome research · 2019Article
- Computationally-assisted discovery and structure elucidation of natural products.Journal of natural medicines · 2019Review
- Competition among Nasal Bacteria Suggests a Role for Siderophore-Mediated Interactions in Shaping the Human Nasal Microbiota.Applied and environmental microbiology · 2019Article
- Toward a global picture of bacterial secondary metabolism.Journal of industrial microbiology & biotechnology · 2019Article
- Analysis of the Genome and Metabolome of Marine Myxobacteria Reveals High Potential for Biosynthesis of Novel Specialized Metabolites.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
High-throughput proteomics is made possible by a combination of modern mass spectrometry instruments capable of generating many millions of tandem mass (MS(2)) spectra on a daily basis and the increasingly sophisticated associated software for their automated identification. Despite the growing accumulation of collections of identified spectra and the regular generation of MS(2) data from related peptides, the mainstream approach for peptide identification is still the nearly two decades old approach of matching one MS(2) spectrum at a time against a database of protein sequences. Moreover, database search tools overwhelmingly continue to require that users guess in advance a small set of 4-6 post-translational modifications that may be present in their data in order to avoid incurring substantial false positive and negative rates. The spectral networks paradigm for analysis of MS(2) spectra differs from the mainstream database search paradigm in three fundamental ways. First, spectral networks are based on matching spectra against other spectra instead of against protein sequences. Second, spectral networks find spectra from related peptides even before considering their possible identifications. Third, spectral networks determine consensus identifications from sets of spectra from related peptides instead of separately attempting to identify one spectrum at a time. Even though spectral networks algorithms are still in their infancy, they have already delivered the longest and most accurate de novo sequences to date, revealed a new route for the discovery of unexpected post-translational modifications and highly-modified peptides, enabled automated sequencing of cyclic non-ribosomal peptides with unknown amino acids and are now defining a novel approach for mapping the entire molecular output of biological systems that is suitable for analysis with tandem mass spectrometry. Here we review the current state of spectral networks algorithms and discuss possible future directions for automated interpretation of spectra from any class of molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.